Angelini announces the launch on the Italian market of an innovative active wound cleanser developed by the Swiss company APR

Press Swisscompany
  • Published: 15 Feb 2016

The new acid-oxidising solution containing hypochlorous acid and intended for cleansing various kind of wounds, including diabetic foot ulcers, pressure and vascular ulcers, has arrived in Italy. The product has been launched by Angelini and was developed by the Swiss company APR Applied Pharma Research.

15 February 2016 – Rome (Italy) and Balerna (Switzerland). The leading Italian pharmaceutical company Angelini has started the promotion and marketing of a new active wound cleanser in Italian hospitals and wound therapy centres. The innovative acid-oxidising solution contains hypochlorous acid and is indicated for the treatment of chronic wounds. The product has been acquired based on an exclusive partnership between Angelini and the Swiss Company APR Applied Pharma Research, the owner and developer of the proprietary, patented technology TEHCLO®, which enables the production of this acidic and super-oxidising solution. This solution creates an unfavourable environment for the growth of microorganisms and may favor the release of oxygen in the injured tissues. The new acid-oxidising wound cleanser solution is indicated for use in the debridement, irrigation, cleansing and moistening of acute and chronic wounds such as diabetic foot ulcers, pressure ulcers, lower legs ulcers and vascular ulcers.

In the field of Wound Care, Angelini is now able to provide healthcare professionals with a range of wound treatment options from active cleansing, to antisepsis and epithelialisation support.
“With the launch of this product, Angelini aims at strengthening its position in the Wound Care therapeutic area fulfilling a medical need of the scientific community, which encompasses the shift from a passive method of mere cleansing to an active process supporting the physiological healing process.” states Fabio De Luca, Chief Commercial Officer Italy of Angelini Pharma Division.

“We are very proud to see this product on the Italian market“ said Paolo Galfetti, Chief Executive Officer of APR “as it represents a new and unique option to actively cleanse any kind of wound. While cleansing the wound bed, this innovative product is able to modulate the lesion’s microenvironment contributing to the control of the microbial burden, protecting from the risk of local infection, as well as sustaining physiological healing. We believe that this product, for its adaptable use along the continuum of wound care, offers the opportunity to exploit the growth forecasted in the wound cleansing market on a European basis, which is expected to hit a total value of $220 Mi in 2019”.

The new acid-oxidising solution has been developed based on APR’s proprietary patented technology TEHCLO®, enabling the production of an acidic and super-oxidising solution characterized by pH<3, RedOx >1000mV and stabilised hypochlorous acid (>95% of free chlorine species).
It is intended for use in debridement, irrigation, cleansing and moistening of acute and chronic wounds (e.g. diabetic foot ulcers, pressure ulcers, lower leg ulcers, vascular ulcers), post-surgical wounds, cuts, abrasions, burns and other lesions. As it contains hypochlorous acid as a preservative, it can prevent wound contamination by exerting a local antimicrobial effect on the wound surface. The convenient and easy-to-use spray formulation completes the product’s profile, providing healthcare professionals with a new tool for optimised wound care.
The product is certified in the EU as a Class III Medical Device according to rigorous European regulations.

APR is a Swiss, independent developer of science driven, patent protected healthcare products. The company identifies, develops and licenses science driven, value added products designed to address patient or consumer needs in niche or rare therapeutic areas on a global level. In particular, APR’s business model is currently focused on 2 (two) pillars: (i) internally developed and financed (alone or together with our co-development partners) proprietary, value added products to be licensed to healthcare companies for their commercialization, and (ii) support to third party projects by offering added value R&D services under contract and fee for service arrangements. APR has a balanced pipeline of revenue generating branded products marketed in all major markets combined with a compelling pipeline of products at different stages of development. APR has entered into licensing and partnership agreements with pharmaceutical companies in over 70 countries with international sales.

For press releases and other company information, please visit: